Ertugliflozin
Ertugliflozin
Ertugliflozin (pronounced er-tug-li-flo-zin) is an antidiabetic drug used in the treatment of type 2 diabetes. It is marketed under the brand name Steglatro.
Etymology
The name Ertugliflozin is derived from the chemical structure of the drug, which is a member of the class of compounds known as gliflozins or SGLT2 inhibitors. The prefix "Ertu-" is likely a proprietary designation.
Pharmacology
Ertugliflozin works by inhibiting the sodium-glucose transport proteins (SGLT2) in the kidneys, which leads to the excretion of glucose in the urine and thus lowers blood glucose levels.
Related Terms
- SGLT2 inhibitors: A class of drugs that includes Ertugliflozin. Other drugs in this class include Canagliflozin and Dapagliflozin.
- Type 2 diabetes: A chronic condition that Ertugliflozin is used to treat. It is characterized by high blood sugar, insulin resistance, and relative lack of insulin.
- Antidiabetic drug: A broad category of medications, including Ertugliflozin, used to treat diabetes.
Side Effects
Common side effects of Ertugliflozin include urinary tract infections, yeast infections, and increased urination. More serious side effects may include ketoacidosis, kidney problems, and increased cholesterol levels.
See Also
External links
- Medical encyclopedia article on Ertugliflozin
- Wikipedia's article - Ertugliflozin
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski